AR049354A1 - VACUNACONTRA PAPILOMAVIRUS HUMANO(VPH) Y PROCEDIMIENTO DE PREPARACIoN - Google Patents

VACUNACONTRA PAPILOMAVIRUS HUMANO(VPH) Y PROCEDIMIENTO DE PREPARACIoN

Info

Publication number
AR049354A1
AR049354A1 ARP050102434A ARP050102434A AR049354A1 AR 049354 A1 AR049354 A1 AR 049354A1 AR P050102434 A ARP050102434 A AR P050102434A AR P050102434 A ARP050102434 A AR P050102434A AR 049354 A1 AR049354 A1 AR 049354A1
Authority
AR
Argentina
Prior art keywords
hpv
vaccinacontra
preparation procedure
human papilomavirus
human
Prior art date
Application number
ARP050102434A
Other languages
English (en)
Spanish (es)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0413510.9A external-priority patent/GB0413510D0/en
Priority claimed from US11/114,301 external-priority patent/US20050287161A1/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AR049354A1 publication Critical patent/AR049354A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP050102434A 2004-06-16 2005-06-14 VACUNACONTRA PAPILOMAVIRUS HUMANO(VPH) Y PROCEDIMIENTO DE PREPARACIoN AR049354A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0413510.9A GB0413510D0 (en) 2004-06-16 2004-06-16 Vaccine
US11/114,301 US20050287161A1 (en) 2002-12-20 2005-04-26 Vaccine

Publications (1)

Publication Number Publication Date
AR049354A1 true AR049354A1 (es) 2006-07-19

Family

ID=35160037

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102434A AR049354A1 (es) 2004-06-16 2005-06-14 VACUNACONTRA PAPILOMAVIRUS HUMANO(VPH) Y PROCEDIMIENTO DE PREPARACIoN

Country Status (18)

Country Link
EP (1) EP1758609B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2008502633A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20070029254A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR049354A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2005253723B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0512042B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2566620C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (2) FR15C0084I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL179138A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (3) LU92899I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA28692B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA06014515A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO20070195L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20060434A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL1758609T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2420313C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG153837A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2005123125A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG159529A1 (en) * 2005-04-26 2010-03-30 Glaxosmithkline Biolog Sa Vaccine
WO2010012780A1 (en) * 2008-07-31 2010-02-04 Glaxosmithkline Biologicals S.A. Vaccine against hpv
PL2444103T3 (pl) * 2009-06-19 2018-05-30 Eyegene Inc. Szczepionka przeciwko rakowi szyjki macicy
KR20130142104A (ko) * 2010-07-15 2013-12-27 브리티쉬 콜롬비아 캔써 에이전시 브랜치 인간 파필로마바이러스 e7 항원 조성물 및 이의 용도
KR20150076244A (ko) 2012-10-30 2015-07-06 레드박스 게엠베하 인간 시토메갈로바이러스 감염에 대한 재조합 입자 기재 백신
MY195018A (en) * 2014-10-24 2023-01-03 Hpvvax Llc Cancer and skin lesion treatment
CN107188966B (zh) 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
CA2510457C (en) * 2002-12-20 2011-12-06 Glaxosmithkline Biologicals S.A. Hpv-16 and -18 l1 vlp vaccine

Also Published As

Publication number Publication date
FR15C0082I2 (fr) 2016-10-28
EP1758609B1 (en) 2012-10-03
FR15C0084I2 (fr) 2016-10-28
RU2420313C2 (ru) 2011-06-10
BRPI0512042A (pt) 2008-02-06
BRPI0512042B8 (pt) 2021-05-25
EP1758609A1 (en) 2007-03-07
RU2006143804A (ru) 2008-08-20
PL1758609T3 (pl) 2013-02-28
PE20060434A1 (es) 2006-06-08
FR15C0082I1 (fr) 2016-01-08
FR15C0084I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2016-01-08
MXPA06014515A (es) 2007-03-23
LU92899I2 (fr) 2016-03-08
CA2566620A1 (en) 2005-12-29
IL179138A0 (en) 2007-03-08
LU92900I2 (fr) 2016-03-08
SG153837A1 (en) 2009-07-29
AU2005253723B2 (en) 2011-01-20
WO2005123125A1 (en) 2005-12-29
LU92898I2 (fr) 2016-03-08
NO20070195L (no) 2007-01-15
AU2005253723A1 (en) 2005-12-29
BRPI0512042B1 (pt) 2019-01-22
MA28692B1 (fr) 2007-06-01
JP2008502633A (ja) 2008-01-31
CA2566620C (en) 2014-03-11
KR20070029254A (ko) 2007-03-13

Similar Documents

Publication Publication Date Title
MX2023008895A (es) Conjugado de sustancia bioactiva, metodo de preparacion y uso del mismo.
CY1111433T1 (el) Φαρμακευτικο τυποποιημενο παρασκευασμα δεσιταβινης
RS51569B (en) Compositions comprising crystalline trans-(+/-)-delta-9-tetrahydrocannabinol
AR109263A2 (es) Composición que comprende moxidectina
WO2021262826A3 (en) 1'-cyano nucleoside analogs and uses thereof
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
GB2448255A (en) Compositions and methods relating to treatment of cancer and infectious diseases
PA8588601A1 (es) Administracion combinada de una indolinona junto a un agente quimioterapeutico para el tratamiento de enfermedades de proliferacion celular
CU20090209A7 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
CR9022A (es) Derivados de sulfonamida novedosos como moduladores de receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
AR059203A1 (es) Composiciones para uso vaginal
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
ECSP045300A (es) Antígenos virales
ECSP099663A (es) Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y métodos para utilizar la misma
CU20090112A6 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
SE0402762D0 (sv) Indazole sulphonamide derivatives
PE20110677A1 (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
AR042530A1 (es) Vacuna que comprende particulas viroides del virus papiloma humano 16 y 18
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
CO6341567A2 (es) Vacuna contra el virus de papiloma humano
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
AR049354A1 (es) VACUNACONTRA PAPILOMAVIRUS HUMANO(VPH) Y PROCEDIMIENTO DE PREPARACIoN
SE0300098D0 (sv) Use of cyclin D1 inhibitors
UY29181A1 (es) Derivados de bencenosulfonamidas n-sustituidos, composiciones que los contienen, procesos de preparación y aplicaciones

Legal Events

Date Code Title Description
FA Abandonment or withdrawal